Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study

INTRODUCTION: The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). METHODS: PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled, multicenter, dose-finding, phase 2b study. Adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dicpinigaitis, Peter V., Morice, Alyn H., Smith, Jaclyn A., Sher, Mandel R., Vaezi, Michael, Guilleminault, Laurent, Niimi, Akio, Gude, Kerstin, Krahn, Ulrike, Saarinen, Riitta, Pires, Philippe Vieira, Wosnitza, Melanie, McGarvey, Lorcan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Chronic Cough
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234230/
https://www.ncbi.nlm.nih.gov/pubmed/37261531
http://dx.doi.org/10.1007/s00408-023-00621-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234230/
https://www.ncbi.nlm.nih.gov/pubmed/37261531
http://dx.doi.org/10.1007/s00408-023-00621-x

Ejemplares similares